Raseinių vaistinė - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 145,149 | 156,217 | 184,344 | 184,186 | 236,298 | 275,413 | 131,017 | 32,146 |
| Profit before tax | 1,624 | 2,830 | -251 | -4,283 | -1,252 | -10,951 | -2,590 | 1,242 |
| Net profit | 1,624 | 2,830 | -251 | -4,283 | -1,252 | -10,951 | -2,590 | 1,167 |
| Equity | 72,296 | 75,127 | 74,876 | 70,592 | 69,340 | 58,975 | 56,385 | 57,552 |
| Liabilities | 29,369 | 26,833 | 20,912 | 31,743 | 42,564 | 30,855 | 781 | 1,544 |
| Non-current assets | 37,420 | 35,666 | 33,912 | 32,158 | 30,404 | 27,445 | 30,702 | 28,581 |
| Current assets | 64,245 | 66,294 | 61,876 | 70,177 | 81,500 | 61,853 | 26,370 | 30,405 |
| Total assets | 101,665 | 101,960 | 95,788 | 102,335 | 111,904 | 89,298 | 57,072 | 58,986 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 13,688 | 14,649 | 8,831 |
| Social insurance contributions | - | - | - | - | - | 13,429 | 963 | - |
|
Financial indicators
|
||||||||
| Revenue change y/y | -23.4% | +7.6% | +18.0% | -0.1% | +28.3% | +16.6% | -52.4% | -75.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 1.6% | 2.8% | -0.3% | -4.2% | -1.1% | -12.3% | -4.5% | 2.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 2.2% | 3.8% | -0.3% | -6.1% | -1.8% | -18.6% | -4.6% | 2.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 1.1% | 1.8% | -0.1% | -2.3% | -0.5% | -4.0% | -2.0% | 3.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 1.1% | 1.8% | -0.1% | -2.3% | -0.5% | -4.0% | -2.0% | 3.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 0.4 | 0.3 | 0.4 | 0.6 | 0.5 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 17,245 | 24,345 | 36,869 | 32,989 | 39,383 | 63,557 | 62,889 | 32,146 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Raseinių vaistinė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-10-28 | 2022-11-07 | 0.32 |
| 2022-07-18 | 2022-07-20 | 0.26 |
Raseinių vaistinė - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-02-27 | 2026-02-27 | 72.0 |
| 2026-02-21 | 2026-02-26 | 2.0 |
| 2025-02-28 | 2025-03-15 | 0.93 |
| 2025-02-20 | 2025-02-25 | 0.93 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Raseiniu vaistine, UAB, a Private Limited Liability Company (code 172335325), operates in retail sale of pharmaceutical products. In 2025, the company generated revenue of €32.1K and reported net profit of €1.2K, which resulted in a 3.6% profit margin. This was a return to profitability after losses in 2024 and 2023, when net profit stood at -€2.6K and -€11.0K respectively. Revenue, however, continued to contract sharply, falling from €275.4K in 2023 to €131.0K in 2024 and then to €32.1K in 2025, with year-on-year revenue growth of -75.5% in the latest year and a two-year decline of -88.3%. The balance sheet remained conservatively financed, with equity of €57.6K, liabilities of €1.5K and total assets of €59.0K in 2025. The equity ratio was 97.6% and debt-to-equity 0.03, indicating very low leverage. Asset turnover was 0.54x, while revenue per employee was €32.1K and profit per employee €1.2K.